25 C
New York
Friday, June 12, 2026

Tag: surveillance

newssourceFORcompanyinformationcontent1marketreleases

Dimensional Fund Advisors Ltd. : Form 8.3 – UNITE GROUP PLC/THE – Ordinary Shares

FORM 8.3

Form 8.5 (EPT/RI) – Apax Global Alpha Limited

FORM 8.5 (EPT/RI)

Man Group PLC : Form 8.3 – Deliveroo Plc

FORM 8.3

June 2025 Quarterly Exploration Results

82km of drilling and $9M invested in resource development and exploration in Q4, FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...

Form 8.3 – Life Science REIT Plc

8.3

Draganfly Secures Strategic Military Order for Commander 3XL UAV Systems

Tampa Bay, Florida, July 22, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions and systems developer, today announced the sale of Commander 3XL Unmanned Aerial Vehicle (UAV) systems to a globally recognized defense contractor specializing in persistent surveillance technologies for military operations.

Form 8.5 (EPT/RI) – Apax Global Alpha Limited

FORM 8.5 (EPT/RI)

Form 8.5 (EPT/RI) – Greencore Group Plc

FORM 8.5 (EPT/RI)

Form 8.3 – Dowlais Group plc

FORM 8.3

Baseus Expands Smart Security Lineup with Sun-powered S2 and S1 Lite Cameras

LAS VEGAS, July 20, 2025 /PRNewswire/ -- When it comes to keeping your home and loved ones safe, you need to rely on a...

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Smart Factory Market worth $169.73 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global smart factory market is projected to reach USD 104.42 billion in 2025 and USD 169.73...

Smart Factory Market worth $169.73 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global smart factory market is projected to reach USD 104.42 billion in 2025 and USD 169.73...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSurveillance

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers